Sarepta Obtains Broader DMD Label For Elevidys

Jun 21 2024

• By Joseph Haas

Listen to this article

The gene therapy is now approved for all ambulatory boys with Duchenne muscular dystrophy ages 4 and older. The revised label also includes accelerated approval for non-ambulatory patients.

Expanded — Expanded label for Elevidys covers all ambulatory DMD patients 4 and older • Source: Shutterstock

Sarepta Therapeutics, Inc. obtained expanded US Food and Drug Administration approval of its Duchenne muscular dystrophy gene therapy Elevidys in ambulatory boys aged 4 and older, overcoming concerns after a confirmatory trial missed its primary endpoint last October. The 20 June FDA decision, which built on the June 2023 accelerated approval that cleared the drug for ambulatory boys aged 4-5, also provides a new accelerated approval for Elevidys to treat non-ambulatory boys ages 4 and older.

[Sidebar#SC149277]

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again
Jun 14 2025
• By Nabil
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
Mar 10 2025
• By Dexter Jie Yan
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch
Mar 10 2025
• By Alexandra Shimmings
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.

More from Scrip

sponsored
Sponsored by :
Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.